The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Abstract
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-refractory tumours 1,2. We are testing melanoma FixVac (BNT111)-an intravenously administered liposomal RNA (RNA-LPX) vaccine, which targets four non-mutated, tumour-associated antigens that are prevalent in melanoma-in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT trial, ClinicalTrials.gov identifier NCT02410733). We report here data from an exploratory interim analysis that show that melanoma FixVac, alone or in combination with blockade of the checkpoint inhibitor PD1, mediates durable objective responses in checkpoint-inhibitor (CPI)-experienced patients with unresectable melanoma. Clinical responses are accompanied by the induction of strong CD4+ and CD8+ T cell immunity against the vaccine antigens. The antigen-specific cytotoxic T-cell responses in some responders reach magnitudes typically reported for adoptive T-cell therapy, and are durable. Our findings indicate that RNA-LPX vaccination is a potent immunotherapy in patients with CPI-experienced melanoma, and suggest the general utility of non-mutant shared tumour antigens as targets for cancer vaccination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical trials of mRNA-based immunotherapeutics encoding unmutated full-length TAAs in checkpoint inhibitor-treated melanoma [18] and individualised mRNA-based immunotherapeutics encoding patient-specific mutated tumour neoantigens in pancreatic and lung cancer [19, 20] have shown encouraging results.”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [18]
In the citing paper
“Previous studies have demonstrated that the use of BNT111 alone or in combination with PD-1 antibody can activate tumor antigen-specific CD4+ and CD8+ T cells and elicit durable immune responses.345,350–352”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [345]
In the citing paper
“For example, FixVac, which was developed based on the RNA-LPX formulation, is a systemic mRNA vaccine encoding four non-mutated antigens of melanoma200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“After the eighth immunization, more than 75% of patients generated immune responses against at least one tumour-associated antigen, and CD8+ T cells played a major role in high-magnitude T cell responses200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“Moreover, a combination of FixVac/anti-programmed cell death protein 1 (PD1) antibody augmented the antitumour effect of FixVac, resulting in a >35% tumour regression rate in immune checkpoint inhibitor-experienced patients200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“The interim analysis from the phase I trial (NCT02410733) showed that the metabolic activity of the spleen increased post the sixth immunization, indicating targeted delivery of FixVac and activation of resident immune cells200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationMiXCR: software for comprehensive adaptive immunity profiling
Bolotin, D. A., Poslavskii, S., Mitrophanov, I., Shugay, M., Mamedov, I. Z., Putintseva, E. V., & Chudakov, D. M. (2015) · Nature Methods · doi:10.1038/nmeth.3364 · Cited by 1,730
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Cited by
Sorted by citations
Items 501–600 of 1,000
Considerations on the Design of Lipid-based mRNA Vaccines Against Cancer
Meulewaeter, S., Zhang, Y., Wadhwa, A., Fox, K., Lentacker, I., Harder, K. W., Cullis, P. R., Smedt, S. C. D., Cheng, M. H. Y., & Verbeke, R. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168385 · Cited by 13
Qu, H., Jiang, J., Zhan, X., Liang, Y., Guo, Q., Liu, P., Lü, L., Yang, Y., Xu, W., Zhang, Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54222-6 · Cited by 13
The future of genetic medicines delivered via targeted lipid nanoparticles to leukocytes
Tarab‐Ravski, D., Stotsky‐Oterin, L., Elisha, A., Kundoor, G. R., Ramishetti, S., Hazan‐Halevy, I., Haas, H., & Peer, D. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.014 · Cited by 13
Self-citationZeng, Q., Zhang, S., Leng, N., & Xing, Y. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104576 · Cited by 13
Wei, Z., Zhang, S., Wang, X., Xue, Y., Dang, S., & Zhai, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524317 · Cited by 16
Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines
Twilhaar, M. K. N., Czentner, L., van Nostrum, C. F., Storm, G., & den Haan, J. M. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13070954 · Cited by 13
Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy
Tatlı, Ö., & Doğanay, G. D. (2021) · Molecules · doi:10.3390/molecules26247561 · Cited by 14
mRNA vaccine development for cholangiocarcinoma: a precise pipeline
Tang, T., Huang, X., Zhang, G., Lu, M., & Liang, T. (2022) · Military Medical Research · doi:10.1186/s40779-022-00399-8 · Cited by 13
The peptide woods are lovely, dark and deep: Hunting for novel cancer antigens
Oreper, D., Klaeger, S., Jhunjhunwala, S., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101758 · Cited by 13
Peptide-Based Therapeutic HPV Cancer Vaccine Synthesized via Bacterial Outer Membrane Vesicles
Chen, H., Zheng, X. W., Li, L., Huang, L., Huang, W., & Ma, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s416706 · Cited by 13
Gehrcken, L., Sauerer, T., Schaft, N., & Dörrie, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168679 · Cited by 13
Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application
Xie, N., Shen, G., Huang, C., & Zhu, H. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003708 · Cited by 13
Dendritic cells: the central partner for cancer immunity
Laoubi, L., Gobbini, É., Duplouye, P., Hubert, M., Caux, C., Bendriss‐Vermare, N., Valladeau‐Guilemond, J., & Voissière, A. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2571773 · Cited by 12
Application of Nanoparticles in Tumour Targeted Drug Delivery and Vaccine
Tu, Y., Yao, Z., Yang, W., Tao, S., Li, B., Wang, Y., Su, Z., & Li, S. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2022.948705 · Cited by 13
Lei, J., Qi, S., Yu, X., Gao, X., Yang, K., Zhang, X., Cheng, M., Bai, B., Feng, Y., Lu, M., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202318515 · Cited by 12
Nanomedicine-based cancer immunotherapy: a bibliometric analysis of research progress and prospects
Chen, C., Yuan, P., & Zhang, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1446532 · Cited by 12
Zhang, W., Park, H., An, E., Kim, S., Ryu, D.-Y., Kim, D., Lim, D., Hwang, J., Kwak, M., You, S., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135922 · Cited by 12
Rapid Hemostasis Tumor In Situ Hydrogel Vaccines for Colorectal Cancer Chemo-Immunotherapy
Qiu, W., Zheng, Y., Shen, F., Wang, Z., Huang, Q., Guo, W., Wang, Q., Yang, P., He, F., Cao, Z., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c13489 · Cited by 12
Shi, G., Xu, Y., Qiu, H., Cao, F., Xiao, Z.-X., Zhang, C., & Zha, G. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.12.003 · Cited by 13
Younis, M. A., Sato, Y., Elewa, Y. H. A., & Harashima, H. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01824-w · Cited by 12
Limeres, M. J., Gambaro, R. C., Svensson, M., Ghazi, S. F.-E., Pretsch, L., Frank, D., Islan, G. A., Berti, I. R., Bros, M., Tam, Y. K., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.027 · Cited by 13
Mühlenbruch, L., Kors, T. A., Dubbelaar, M. L., Bichmann, L., Kohlbacher, O., Bens, M., Thomas, J., Ezić, J., Kraus, J. M., Kestler, H. A., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02197-y · Cited by 12
Liposome-based nanomedicine for immune checkpoint blocking therapy and combinatory cancer therapy
Zhou, H., Yu, C., & Wei, H. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123818 · Cited by 12
General sites of nanoparticle biodistribution as a novel opportunity for nanomedicine
Fleischmann, D., & Göpferich, A. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.05.027 · Cited by 12
Wang, F. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03108-6 · Cited by 11
Bibliometric analysis of RNA vaccines for cancer
Yang, X., Kang, J., Xing, Z., Sun, Y., Liu, Z., Li, N., & Niu, J.-R. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2231333 · Cited by 11
Pelka, S., & Guha, C. (2023) · Biomedicines · doi:10.3390/biomedicines11082245 · Cited by 11
Immune Checkpoint Inhibitors and Vaccination: Assessing Safety, Efficacy, and Synergistic Potential
New, J., Shenton, L. M., Ksayer, R., Wang, J., Zakharia, K., Nicholson, L. J., & Pandey, A. C. (2024) · Vaccines · doi:10.3390/vaccines12111270 · Cited by 11
An mRNA vaccine encoding proteasome-targeted antigen enhances CD8+ T cell immunity
Ling, J., Chen, H., Huang, M., Wang, J., & Du, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.074 · Cited by 12
Exploring the promise of lipoplexes: From concept to clinical applications
Al-Shihabi, A. M., Al-Mohaya, M., Haider, M. A., & Demiralp, B. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125424 · Cited by 11
Smart nanoparticle delivery of cancer vaccines enhances tumor immune responses: a review
Qiu, J., & Wu, C. (2025) · Frontiers in Nanotechnology · doi:10.3389/fnano.2025.1564267 · Cited by 12
Therapeutic mRNA vaccine applications in oncology
Elliott, L. A., Foster, T. P., Castillo, P., Méndez-Gómez, H., & Sayour, E. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.044 · Cited by 11
Pati, S. S., Dhal, S., Pattnaik, R., Tripathy, S., & Kumar, S. (2025) · Current Medical Science · doi:10.1007/s11596-025-00112-5 · Cited by 11
Advancing Cancer Immunotherapy Using Lipid Nanoparticle-Based Approaches
Prazeres, P. H. D. M., da Silva, G. C., Azevedo, G., da Silva, N. J. A., Costa, P. A. C., da Silva, W., Lobo, A. O., & Guimarães, P. P. G. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s541061 · Cited by 11
Chen, X., Yang, H., Song, X., Liang, H., Wei, Y., Lu, J., Barz, M., Jin, R., & Nie, Y. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.107753 · Cited by 12
Shen, Y., Yu, L., Xu, X., Yu, S., & Yu, Z. (2022) · Cancer Innovation · doi:10.1002/cai2.26 · Cited by 12
Hyperbranched Polymer‐Based Vaccines for Cancer Immunotherapy
Wang, Z., Guo, Y., Shen, M., Wang, Y., & Shi, X. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300188 · Cited by 11
Loquai, C., Hassel, J. C., Bruck, P. T., Derhovanessian, E., Ćuk, K., Lörks, V., Sikorski, J., Gold, M., Maurus, D., Schwarck-Kokarakis, D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-sitc2021.549 · Cited by 11
Self-citationYang, J., Sun, J., Zhu, J., Du, Y., Tan, Y., Wei, L., Zhao, Y., Hou, Q., Zhang, Y., Sun, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.22.489232 · Cited by 11
Cho, S., Kwak, W., Yoon, H., Lee, J., Lee, S., Park, H., Jo, S., Lee, Y., Seo, Y., Cho, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202506426 · Cited by 10
RNA-based Therapeutics: Past, Present and Future Prospects, Challenges in Cancer Treatment
Goel, A., Rastogi, A., Jain, M., & Niveriya, K. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010291042240130171709 · Cited by 10
Activated B-Cells enhance epitope spreading to support successful cancer immunotherapy
Kellermann, G., Leulliot, N., Cherfils‐Vicini, J., Blaud, M., & Brest, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1382236 · Cited by 10
The dawn of a new Era: mRNA vaccines in colorectal cancer immunotherapy
Song, J., Zhang, Y., Zhou, C., Zhan, J., Cheng, X., Huang, H., Mao, S., & Zong, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112037 · Cited by 10
He, Y.-R., Xia, H., Yun, P., Xu, Y., Ma, W. M. J., Xiao, Z.-X., & Zha, G. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070940 · Cited by 10
Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides
Fu, Q., Luo, Y., Li, J., Zhang, P., Tang, S., Song, X., Fu, J., Liu, M., Mo, R., Wei, M. Q., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2385654 · Cited by 10
Ostroumov, D., Benne, N., Vigario, F. L., Escalona-Rayo, O., Dodz, K., Sauer, S., Suhl, L., Wedemeyer, H. H., Kühnel, F., Slütter, B., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01249-4 · Cited by 10
Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review
Gomez-Randulfe, I., Lavender, H., Symeonides, S. N., & Blackhall, F. H. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251316988 · Cited by 10
The Bright Future of mRNA as a Therapeutic Molecule
Vélez, D. E., Torres, B. L., & Hernández, G. (2025) · Genes · doi:10.3390/genes16040376 · Cited by 11
Nanovaccines: Antigen selection, stabilization, adjuvantation, formulation, and evaluation
Lu, L., Yang, M., Deng, D., Shi, X., Lovell, J. F., & Jin, H. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216806 · Cited by 10
Tumor-responsive nanomedicines for cancer therapy: design principles and therapeutic advances
Liu, Y., Wang, Y., Gemingnuer, A., Wang, H., & Meng, X. (2025) · Biomedical Materials · doi:10.1088/1748-605x/adf387 · Cited by 10
Wang, Z., Liu, X., Jin, J., Liu, X., Liu, C., Xie, F., Wang, X., An, F., Xiao, B., Cheng, H., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202420308 · Cited by 10
Ahmed, S., Gozal, D., & Khalyfa, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110316 · Cited by 10
Liu, S., Zhang, L., Wu, W., Chen, M. Y., & Qian, F. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102803 · Cited by 11
Melanoma: Pathogenesis and Targeted Therapy
Fu, Y., Liu, J., Mo, Z., Wang, B., Deng, Y., & Jiang, Y. (2026) · MedComm · doi:10.1002/mco2.70566 · Cited by 11
Mallet, M., Boulos, R. E., Alcazer, V., Bonaventura, P., Estornes, Y., Chuvin, N., & Depil, S. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.008 · Cited by 12
18F-FDG PET Visualizes Systemic STING Agonist-Induced Lymphocyte Activation in Preclinical Models
Le, T. M., Lee, H. R., Abt, E. R., Rashid, K., Creech, A. L., Liang, K., Cui, J., Cho, A. E.-H., Liu, W., Labora, A. N., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264121 · Cited by 10
Fu, J., Chen, F., Lin, Y., Gao, J., Chen, A., & Yang, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04325-2 · Cited by 10
Zhao, J., Xu, R., Lu, T., Wang, J., & Zhang, L. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1113 · Cited by 10
Next‐Generation Vaccines: Nanovaccines in the Fight against SARS‐CoV‐2 Virus and beyond SARS‐CoV‐2
Mufamadi, M. S., Ngoepe, M. P., Nobela, O., Maluleke, N., Phorah, B., Methula, B., Maseko, T., Masebe, D. I., Mufhandu, H. T., & Katata‐Seru, L. (2023) · BioMed Research International · doi:10.1155/2023/4588659 · Cited by 10
Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta‐analysis
Zhang, T., Xu, H., Zheng, X., Xiong, X., Zhang, S., Yi, X., Li, J., Wei, Q., & Ai, J. (2023) · MedComm · doi:10.1002/mco2.286 · Cited by 10
mRNA-Based Cancer Vaccines: Advancements and Prospects
Wu, L., Yi, W., Yao, S., Xie, S., Peng, R., Zhang, J., & Tan, W. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c03296 · Cited by 10
Key considerations for a prostate cancer mRNA vaccine
Lin, G., Elkashif, A., Saha, C., Coulter, J. A., Dunne, N., & McCarthy, H. O. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104643 · Cited by 10
Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer
Mainini, F., Santis, F. D., Fucà, G., Nicola, M. D., Rivoltini, L., & Eccles, M. R. (2021) · Cancers · doi:10.3390/cancers13153765 · Cited by 11
Stasevich, E. M., Uvarova, A. N., Murashko, M. M., Khabusheva, E., Sheetikov, S. A., Prassolov, V., Kuprash, D. V., Демин, Д. Э., & Schwartz, A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094624 · Cited by 10
Shared epitopes create safety and efficacy concerns in several cancer vaccines
Kellermann, G., Mograbi, B., Hofman, P. M., & Brest, P. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012217 · Cited by 10
Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma
Lutz, J., Feist, R. K., Sonntag, T., Peguero-Sánchez, E., Wolter, K., Bick, R., Bauer, J., Walz, J. S., & Heidenreich, R. (2025) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-025-04178-x · Cited by 9
“Clinical trials of mRNA-based immunotherapeutics encoding unmutated full-length TAAs in checkpoint inhibitor-treated melanoma [18] and individualised mRNA-based immunotherapeutics encoding patient-specific mutated tumour neoantigens in pancreatic and lung cancer [19, 20] have shown encouraging…”
Immunity in acute myeloid leukemia: Where the immune response and targeted therapy meet
Fink, A., Hung, E., Singh, I., & Ben‐Neriah, Y. (2021) · European Journal of Immunology · doi:10.1002/eji.202048945 · Cited by 10
Personalized Neoantigen DNA Cancer Vaccines: Current Status and Future Perspectives
Viborg, N., Kleine‐Kohlbrecher, D., & Rønø, B. (2024) · Journal of Cellular Immunology · doi:10.33696/immunology.6.188 · Cited by 10
Peters, D., Kranz, L. M., Eisel, D., Diken, M., Kreiter, S., Türeci, Ö., Şahin, U., & Vormehr, M. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0701 · Cited by 9
Self-citationTang, W., Wu, Q., Liang, A., Shi, J., Chen, J., Zhu, X. M., & Mao, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104772 · Cited by 9
Bioengineering approaches to trained immunity: Physiologic targets and therapeutic strategies
Knight, H. R., Kim, M., Kannan, N., Taylor, H. B., Main, H., Azcue, E., & Esser-Kahn, A. P. (2025) · eLife · doi:10.7554/elife.106339 · Cited by 9
PredIG: an interpretable predictor of T-cell epitope immunogenicity
Farriol-Duran, R., Domínguez-Dalmases, C., Cañellas-Solé, A., Vázquez, M., Porta‐Pardo, E., & Guallar, V. (2025) · Genome Medicine · doi:10.1186/s13073-025-01569-8 · Cited by 9
Pandey, A., Rai, S. K., Ma, L., Higa, L., Khadka, V. S., Yang, H., & Deng, Y. (2026) · Advanced Science · doi:10.1002/advs.202518960 · Cited by 9
Emerging trends of research on mRNA vaccines: A co-citation analysis
Chen, J., Zhang, T., Lu, Y. Z., Yang, X., & Ouyang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2110409 · Cited by 10
Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response
Wang, Q., Liu, Y., Wang, J., & Wang, H. (2023) · ChemMedChem · doi:10.1002/cmdc.202200673 · Cited by 9
The Dawning of a New Enterprise: RNA Therapeutics for the Skin
Kieser, R. E., Khan, S., Bejar, N., & Kiss, D. (2023) · Journal of Dermatology and Skin Science · doi:10.29245/2767-5092/2023/1.1168 · Cited by 9
MicroRNA therapeutics and nucleic acid nano-delivery systems in bacterial infection: a review
Li, Z., Lei, Z., Cai, Y., Cheng, D., & Sun, T. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00694h · Cited by 9
Recent progress in cancer immunotherapy: Application of nano-therapeutic systems
Ghafelehbashi, R., Salehi, M., Kouhi, M., Naeini, A. A., Sajadi-Javan, Z. S., & Nejatidanesh, F. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105184 · Cited by 9
Mixich, L., Boonstra, E., Masuda, K., Li, S., Nakashima, Y., Meng, F., Sakata, M., Goda, T., Uchida, S., & Cabral, H. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.3c01102 · Cited by 9
Are we getting closer to a successful neoantigen cancer vaccine?
Manoutcharian, K., & Gevorkian, G. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101254 · Cited by 9
Hou, Y., Wang, Z., Chen, Z., Shuai, L., Pei, Y., Sun, B., Jiang, Y., & Wang, H. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00426 · Cited by 9
The Road Ahead in Pancreatic Cancer: Emerging Trends and Therapeutic Prospects
Do, C. T. P., Prochnau, J. Y., Domínguez, A. M., Wang, P., & Rao, M. K. (2024) · Biomedicines · doi:10.3390/biomedicines12091979 · Cited by 9
The Landmark Series: Cancer Vaccines for Solid Tumors
Ninmer, E. K., Xu, F., & Slingluff, C. L. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16712-9 · Cited by 10
Hoehn, S. J., Krul, S. E., Skory, B. J., & Crespo‐Hernández, C. E. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202103667 · Cited by 9
Guo, D., Liu, Y., Jiang, Y., Zheng, S., Xu, T. C., Zhu, J., Chen, P., Huang, P. C., & Zhang, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-5831 · Cited by 9
Odales, J., Servín-Blanco, R., Martínez‐Cortés, F., Valle, J. G., Domínguez‐Romero, A. N., Gevorkian, G., & Manoutcharian, K. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.062 · Cited by 9
Vaccine Boosting CAR-T Cell Therapy: Current and Future Strategies
Ansah, E. O., Baah, A., & Agyenim, E. B. (2023) · Advances in Cell and Gene Therapy · doi:10.1155/2023/8030440 · Cited by 9
Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy
Li, B., Gong, T., Hao, Y., Zhou, X., & Cheng, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.721249 · Cited by 9
Thrift, W. J., Lounsbury, N., Broadwell, Q., Heidersbach, A. J., Freund, E. C., Abdolazimi, Y., Phung, Q. T., Chen, J., Capietto, A.-H., Tong, A.-J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.08.519673 · Cited by 9
Xu, Z., Dong, Y., Cui, K., Hu, B., Lu, Y., Liu, X., Shahzad, A., Zhang, J., Duan, Q., Bai, Z., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112183 · Cited by 8
Clinically relevant dosing of miR-145 micelles curbs atherosclerosis in vivo
Suzuki, I., Ashraf, A., Patel, N., Huang, Y., Lam, B., Kim, D., Choroomi, A., Liu, A., Johnson, K., Williams, C., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113930 · Cited by 8
Vaccine therapies for glioma: clinical frontiers and potential breakthrough
Xing, Y., Liu, C., Feng, Y., Li, S., & Chen, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1613332 · Cited by 9
Discrete Immolative Guanidinium Transporters deliver mRNA to specific organs and red blood cells
Li, Z., Ee, A., Amaya, L., Hamad, J. L., Yadav, P. K., Wang, S. K., Chang, H. Y., & Wender, P. A. (2025) · Nature Communications · doi:10.1038/s41467-025-62200-3 · Cited by 8
Leveraging T cells for cancer immunotherapy
Bates, A., Fletcher, N. E., Gao, F., Pinho, M. P., & Dong, T. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00007-z · Cited by 8
Xu, X., An, J., Bai, D., Xu, Y., Wu, T., Yang, H., Yan, Y., Yang, S., Wei, Z., Yao, Y., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114680 · Cited by 8
Immune checkpoint blockades therapy of melanoma
Liu, H., Ou, J., Hung, M., & Chen, X. '. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.02.003 · Cited by 8
Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development
Kreidieh, F., Tawbi, H. A., Alexaki, A., Borghaei, H., & Kandalaft, L. E. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_391278 · Cited by 8
Modulation of immune cells with mRNA nanoformulations for cancer immunotherapy
Han, J., & Park, J. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103014 · Cited by 8
Non‐viral Gene Therapy for Melanoma Using Lysenin from Eisenia Foetida
Ren, M., Yang, L., He, L., Wang, J., Zhao, W., Yang, C. C., Yang, S., Cheng, H., Huang, M., & Gou, M. (2024) · Advanced Science · doi:10.1002/advs.202306076 · Cited by 8
Chen, C., Zhang, Y., Cao, Z., Li, D., Zhu, Y., Jing, H., Li, Y., Li, F., Xu, C., Yang, X., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202406101 · Cited by 8
Metadata
- Authors
- Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., Kranz, L. M., Diken, M., Kreiter, S., Haas, H., Attig, S., Rae, R., Cuk, K., Kemmer-Brück, A., Breitkreuz, A., Tolliver, C., Caspar, J., Quinkhardt, J., Hebich, L., Stein, M., Hohberger, A., Vogler, I., Liebig, I., Renken, S., Sikorski, J., Leierer, M., Müller, V., Mitzel-Rink, H., Miederer, M., Huber, C., Grabbe, S., Utikal, J., Pinter, A., Kaufmann, R., Hassel, J. C., Loquai, C., & Türeci, Ö.
- Affiliations
- BioNTech (Germany) (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- German Cancer Research Center (DE)
- University Hospital Frankfurt (DE)
- ORCID
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 585
- Issue
- 7823
- Pages
- 107-112
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3046115489
- Cited by
- 1,052
- References
- 36
- Citations by year
- 2026: 140 · 2025: 204 · 2024: 191 · 2023: 190 · 2022: 174 · 2021: 131 · 2020: 21
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- RNA vaccines, melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, tumor-associated antigens, cancer immunotherapy, CD4+ T cells, CD8+ T cells, cytotoxic T lymphocyte response
- MeSH terms
- Antigens, Neoplasm, Antineoplastic Agents, Combined Modality Therapy, Humans, Melanoma, Neoplasm Staging, RNA, Neoplasm, T-Lymphocytes, T-Lymphocytes, Cytotoxic, Vaccination, Cancer Vaccines, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
